Selection of the isolate of Staphylococcus hominis for bacteriotherapy in patients with atopic dermatitis

Introduction Staphylococcus aureus plays a significant role in the development of the clinical picture in patients with atopic dermatitis. The use of commensal microflora can be a promising direction in treatment of atopic dermatitis. Aim The aim of this study is the selection of the optimal safe isolate of S. hominis for bacteriotherapy in patients with atopic dermatitis. Material and methods Sensitivity of isolates of S. hominis ssp. hominis to antibacterial drugs was determined by the disk-diffusion method on Mueller–Hinton agar (HiMedia, India). The ability to form a biofilm was determined by measuring the amount of dye absorption by the biofilm on a microplate reader MR-96A (Mindray, China) at a wavelength of 495 nm. Antagonism in vitro was determined by the method of perpendicular strokes on the blood agar. In total, 24 adult volunteers (aged 18 to 60 years) were screened and included in the study. The results were calculated according to the zone of S. aureus growth retardation under the influence of metabolic products of S. hominis ssp. hominis. Results and Discussion As a result of the study of 8 isolates of S. hominis ssp. hominis, which were obtained from the swabs taken from healthy skin of 24 people, one isolate of S. hominis ssp. hominis Hom-2 met all criteria of safety – Hom-2 demonstrated sensitivity to the studied antibiotics and formed a biofilm of low density (OD 0.15), and effectiveness (morphological and cultural properties, antagonistic effect on S. aureus). Conclusions In this work, an isolate of S. hominis ssp. hominis Hom-2 met all criteria of safety and efficacy and will be used in the further study of bacteriotherapy in patients with atopic dermatitis.